Loading
POP-RT, from Mumbai, showed that treating the pelvic lymph nodes as well as the prostate improves disease control in high-risk prostate cancer, reviving a question earlier trials had left unanswered.
POP-RT randomised 224 men with high-risk, node-negative prostate cancer (most staged with PSMA PET) to image-guided prostate-only or whole-pelvic radiotherapy with two years of androgen deprivation. Five-year biochemical failure-free survival was 95 percent with pelvic radiotherapy and 81.2 percent with prostate-only treatment (hazard ratio 0.23), with better disease-free survival and more late urinary toxicity (Murthy and colleagues, Journal of Clinical Oncology 2021).
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
224 enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Biochemical failure-free survival at 5 yearsprimary | Whole-pelvic radiotherapy | 110 | 95% | - | - | - |
| Prostate-only radiotherapy | 114 | 81.2% |
Shares IMRT / IGRT (modern external beam), Prostate cancer and the tag radiation-wave4.
Shares IMRT / IGRT (modern external beam), Prostate cancer and the tag radiation-wave4.
Shares IMRT / IGRT (modern external beam) and the tag radiation-wave4.
Shares IMRT / IGRT (modern external beam) and the tag radiation-wave4.
Shares IMRT / IGRT (modern external beam) and the tag radiation-wave4.
Shares IMRT / IGRT (modern external beam) and the tag radiation-wave4.
Shares IMRT / IGRT (modern external beam) and the tag radiation-wave4.
Shares IMRT / IGRT (modern external beam) and the tag radiation-wave4.